Abstract
Chemotherapy-induced peripheral neurotoxicity (CIPN) is a major clinical problem since it is the dose-limiting side effect of a significant number of antineoplastic drugs. The incidence of CIPN varies depending on the conditions, but severe neuropathy can occur in up to 40% of patients undergoing a polichemotherapy regimen. Moreover, even when CIPN is not a dose-limiting side effect, its onset may severely affect the quality of life of cancer patients and cause chronic discomfort. Currently, no treatment is available which can significantly improve the clinical signs and symptoms of CIPN. In recent years, new agents have been proposed as neuroprotectants, and some of them have been more specifically studied for CIPN. So far, the most interesting results for future applications have been obtained in the pre-clinical studies involving cytokines and growth factors. For several of these drugs, in fact, sound hypotheses have been formulated to support the idea of a protective role on selected neuronal targets. However, this theoretical basis has frequently failed to lead to consistent results in pre-clinical and clinical applications. We will review the state-of-the-art of CIPN treatment with growth factors and focus on the future prospects opened up by the most recent pre-clinical and clinical studies.
Keywords: Chemotherapy, peripheral neuropathy, neurotoxicity, neuroprotection, growth factors
Current Drug Safety
Title: The Role of Growth Factors in the Prevention and Treatment of Chemotherapy-Induced Peripheral Neurotoxicity
Volume: 1 Issue: 1
Author(s): Guido Cavaletti and Paola Marmiroli
Affiliation:
Keywords: Chemotherapy, peripheral neuropathy, neurotoxicity, neuroprotection, growth factors
Abstract: Chemotherapy-induced peripheral neurotoxicity (CIPN) is a major clinical problem since it is the dose-limiting side effect of a significant number of antineoplastic drugs. The incidence of CIPN varies depending on the conditions, but severe neuropathy can occur in up to 40% of patients undergoing a polichemotherapy regimen. Moreover, even when CIPN is not a dose-limiting side effect, its onset may severely affect the quality of life of cancer patients and cause chronic discomfort. Currently, no treatment is available which can significantly improve the clinical signs and symptoms of CIPN. In recent years, new agents have been proposed as neuroprotectants, and some of them have been more specifically studied for CIPN. So far, the most interesting results for future applications have been obtained in the pre-clinical studies involving cytokines and growth factors. For several of these drugs, in fact, sound hypotheses have been formulated to support the idea of a protective role on selected neuronal targets. However, this theoretical basis has frequently failed to lead to consistent results in pre-clinical and clinical applications. We will review the state-of-the-art of CIPN treatment with growth factors and focus on the future prospects opened up by the most recent pre-clinical and clinical studies.
Export Options
About this article
Cite this article as:
Cavaletti Guido and Marmiroli Paola, The Role of Growth Factors in the Prevention and Treatment of Chemotherapy-Induced Peripheral Neurotoxicity, Current Drug Safety 2006; 1 (1) . https://dx.doi.org/10.2174/157488606775252656
DOI https://dx.doi.org/10.2174/157488606775252656 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Withdrawal and Hyperphagia: Lessons from Tobacco and Other Drugs
Current Pharmaceutical Design Stevia as a Natural Sweetener: A Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
CNS & Neurological Disorders - Drug Targets Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19
Current Cardiology Reviews Binary Actin-ADP-Ribosylating Toxins and their Use as Molecular Trojan Horses for Drug Delivery into Eukaryotic Cells
Current Medicinal Chemistry Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Immunotherapy in Bladder Cancer
Current Molecular Pharmacology Amiodarone - A ‘Broad Spectrum’ Antiarrhythmic Drug
Cardiovascular & Hematological Disorders-Drug Targets Contrast Agents in X-Ray Computed Tomography and Its Applications in Oncology
Anti-Cancer Agents in Medicinal Chemistry The Use of Novel Oral Anticoagulants in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Polyglandular Autoimmune Syndromes
Current Immunology Reviews (Discontinued) Hypoxia Inducible Factor-1 as a Therapeutic Target in Cerebral Ischemia
Current Signal Transduction Therapy Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications
Current Diabetes Reviews Risk Stratification in Pulmonary Embolism
Current Respiratory Medicine Reviews Role of Ascorbic Acid in Cardiovascular Performance During Acute Hemorrhage
Vascular Disease Prevention (Discontinued) Platelet Activating Factor/Platelet Activating Factor Receptor Pathway as a Potential Therapeutic Target in Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) New Therapies in SLE
Recent Patents on Inflammation & Allergy Drug Discovery Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy Disease Modification in Rheumatoid Arthritis and Osteoarthritis-Current and Emerging Targets and Therapeutics
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Regulation of Blood Pressure by D5 Dopamine Receptors
Cardiovascular & Hematological Agents in Medicinal Chemistry